Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.

@article{Muscedere2010MortalityAM,
  title={Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.},
  author={J. Muscedere and A. Day and D. Heyland},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2010},
  volume={51 Suppl 1},
  pages={
          S120-5
        }
}
  • J. Muscedere, A. Day, D. Heyland
  • Published 2010
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • Appropriate end points are crucial for the successful interpretation of clinical trials. Choosing end points for therapeutic trials of ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) requires careful consideration, because they are complications of critical illness. It may be difficult to distinguish the consequences of VAP and HAP from manifestations of the underlying illnesses, and it is important to determine their incremental magnitude, to plan for possible… CONTINUE READING
    Ventilator-Associated Pneumonia: A Review
    • 93

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 42 REFERENCES
    Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.
    • 1,129
    • PDF
    Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients
    • 879
    Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.
    • 1,066
    • PDF
    Effect of ventilator-associated pneumonia on mortality and morbidity.
    • 315